|
Other therapies | Ch 11 | |
| Page 1 / 16 | |||
|
|
|||
Many other therapies are used to treat cancer. Their utility is of great importance, in particular in offering patient comfort (see also chapter on palliative care). They are curiously grouped together in this chapter although their action mechanisms and their modalities are very different. In the near future, some of these therapies will benefit from an individual chapter (for instance: targeted treatments).
Diphosphonates are used for treating bone metastases
Classical immunotherapy
Passive non specific immunotherapy
Non specific active immunotherapy
Target treatment
What target specific treatments?
Monoclonal antibodies
Trastuzumab (Herceptin™)
Rituximab (Mabthera™ , Rituxan™ )
Alemtuzumab (Mabcampath™, Campath™)
Cetuximab (Erbitux™)
Active small molecules
STI-571 ou Imatinib mesylate (Glivec™, Gleevec™)
Gefitinib (Iressa™)
Erlotinib (Tarceva™)
Anti-angiogenic treatment
Bevacizumab (Avastin™)
Anti-proteasome treatment
Bortezomib (Velcade™)
Other innovating drugs will sooner or later join this incomplete list over the following months or years. Some data may be incomplete. Thank you to my colleagues who may wish to offer suggestions or remarks.
References |
Index |